Reported Saturday, Protagonist's ICOTYDE Demonstrates Increasing PASI 100 Rates Through Week 52 And Nearly 60% Complete Skin Clearance In Adolescents In Phase 3 ICONIC Program

Protagonist's ICOTYDE has shown increasing PASI 100 rates through Week 52, achieving nearly 60% complete skin clearance in adolescents during its Phase 3 ICONIC program. The one-year Phase 3 data, to be presented at AAD 2026, highlights the treatment's lasting skin clearance and favorable safety profile as a once-daily pill for moderate-to-severe plaque psoriasis. ICOTYDE is noted as the first and only IL-23 receptor-targeted oral peptide.